The new capabilities are available starting today, with some features in beta or public preview.
Comparable long-term effectiveness to standard of care corticosteroids over 5 years Normal growth maintained, in contrast to growth suppression commonly seen with standard of care corticosteroids ...
- Duchenne (SGT-003): 23 participants have been dosed in the INSPIRE DUCHENNE trial as of October 31, 2025; Solid expects to ...
Topline phase 3 results show that the novel nanobody gefurulimab is safe and effective for AChR-antibody-positive myasthenia gravis, but long-term results will be key.
Skilled nursing providers cannot consider technology in a vacuum if they hope to invest wisely and implement solutions that help their organizations ...
Q3 2025 Earnings Call November 3, 2025 5:00 PM ESTCompany ParticipantsTaryn Owen - CEO, President & DirectorCarl Schweihs - ...
Declining mental health, poor work-life balance, a lack of psychological safety and leader support have been reported as the main issues affecting employee health and well-being in contemporary times.